Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: LTR001
MIFTS: 53

Lateral Sclerosis

Categories: Genetic diseases, Neuronal diseases, Rare diseases
Genes Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Lateral Sclerosis

About this section

MalaCards integrated aliases for Lateral Sclerosis:

Name: Lateral Sclerosis 12 15 71
Primary Lateral Sclerosis 12 74 52 53
Adult-Onset Primary Lateral Sclerosis 12 52
Motor Neuron Disease 43 71
Adult-Onset Pls 52

Classifications:

MalaCards categories:
Global: Rare diseases Genetic diseases
Anatomical: Neuronal diseases
See all MalaCards categories (disease lists)


External Ids:

Disease Ontology 12 DOID:230
ICD9CM 34 335.24
MeSH 43 D016472
NCIt 49 C129933
SNOMED-CT 67 81211007
ICD10 32 G12.23
UMLS 71 C0085084 C0154682
Sources

Summaries for Lateral Sclerosis

About this section
NIH Rare Diseases : 52 Primary lateral sclerosis (PLS) is a rare neuromuscular disease that affects the nerve cells that control the voluntary muscles. Problems in the legs (such as weakness, stiffness, spasticity , and balance problems) are often observed first, but hand clumsiness and changes in speech can be early symptoms, as well. The condition is progressive (gradually becomes worse over time); however, affected people have a normal life expectancy. The underlying cause of adult PLS is currently unknown. In most cases, it occurs sporadically in people with no family history of the condition. A subtype of PLS, called juvenile PLS , is caused by changes (mutations ) in the ALS2 gene and is inherited in an autosomal recessive manner. Treatment is based on the signs and symptoms present in each person.

MalaCards based summary : Lateral Sclerosis, also known as primary lateral sclerosis, is related to primary lateral sclerosis, adult, 1 and amyotrophic lateral sclerosis, juvenile, with dementia, and has symptoms including ataxia, myoclonus and hemiplegia. An important gene associated with Lateral Sclerosis is SOD1 (Superoxide Dismutase 1), and among its related pathways/superpathways are Neuroscience and Cytoskeleton remodeling Neurofilaments. The drugs Mexiletine and Minocycline have been mentioned in the context of this disorder. Affiliated tissues include brain, spinal cord and bone, and related phenotypes are behavior/neurological and cellular

Disease Ontology : 12 A motor neuron disease characterized by painless but progressive weakness and stiffness of the muscles of the legs.

Wikipedia : 74 Primary lateral sclerosis (PLS) is a rare neuromuscular disease characterized by progressive muscle... more...

Sources

Related Diseases for Lateral Sclerosis

About this section

Diseases in the Lateral Sclerosis family:

Primary Lateral Sclerosis, Juvenile Primary Lateral Sclerosis, Adult, 1

Diseases related to Lateral Sclerosis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 912)
# Related Disease Score Top Affiliating Genes
1 primary lateral sclerosis, adult, 1 35.1 SOD1 ALS2
2 amyotrophic lateral sclerosis, juvenile, with dementia 34.9 VCP C9orf72
3 frontotemporal dementia and/or amyotrophic lateral sclerosis 3 34.8 PRPH CHCHD10
4 frontotemporal dementia and/or amyotrophic lateral sclerosis 4 34.7 PRPH CHCHD10
5 frontotemporal dementia and/or amyotrophic lateral sclerosis 2 34.7 PRPH CHCHD10
6 amyotrophic lateral sclerosis type 5 34.7 VAPB SPG11 SOD1 SETX ALS2
7 amyotrophic lateral sclerosis type 22 34.7 UBQLN2 PRPH
8 juvenile amyotrophic lateral sclerosis 34.6 SPG11 SIGMAR1 SETX FUS ALS2
9 amyotrophic lateral sclerosis 7 34.5 SPG11 SETX PRPH DCTN1 ALS2
10 amyotrophic lateral sclerosis 19 34.5 UBQLN2 TARDBP SOD1 PRPH C9orf72 ALS2
11 c9orf72-related amyotrophic lateral sclerosis and frontotemporal dementia 34.4 LOC109504728 C9orf72
12 amyotrophic lateral sclerosis 21 34.3 VAPB SPG11 SIGMAR1 SETX PRPH FUS
13 amyotrophic lateral sclerosis 20 34.3 SPG11 SIGMAR1 PRPH HNRNPA1 C9orf72 ALS2
14 amyotrophic lateral sclerosis 12 34.3 VAPB UBQLN2 TARDBP SPG11 SETX FUS
15 amyotrophic lateral sclerosis 16, juvenile 34.2 VCP VAPB UBQLN2 SPG11 SIGMAR1 SETX
16 amyotrophic lateral sclerosis 18 34.2 VAPB UBQLN2 SIGMAR1 SETX PRPH FUS
17 amyotrophic lateral sclerosis 9 34.2 VAPB UBQLN2 SPG11 SOD1 SIGMAR1 SETX
18 amyotrophic lateral sclerosis 11 34.2 VAPB UBQLN2 TARDBP SPG11 SIGMAR1 SETX
19 amyotrophic lateral sclerosis 4, juvenile 34.2 VAPB UBQLN2 TARDBP SPG11 SOD1 SETX
20 amyotrophic lateral sclerosis 17 34.1 VAPB UBQLN2 SPG11 SIGMAR1 SETX PRPH
21 amyotrophic lateral sclerosis 10 with or without frontotemporal dementia 34.0 VAPB UBQLN2 TARDBP SPG11 SOD1 SIGMAR1
22 amyotrophic lateral sclerosis type 14 34.0 VCP VAPB UBQLN2 SIGMAR1 SETX PRPH
23 amyotrophic lateral sclerosis 8 33.9 VAPB UBQLN2 TARDBP SPG11 SOD1 SIGMAR1
24 amyotrophic lateral sclerosis type 15 33.9 VAPB UBQLN2 SPG11 SIGMAR1 SETX PRPH
25 amyotrophic lateral sclerosis type 6 33.9 VAPB UBQLN2 TARDBP SPG11 SOD1 SIGMAR1
26 frontotemporal dementia and/or amyotrophic lateral sclerosis 1 33.4 VCP VAPB UBQLN2 TARDBP SPG11 SOD1
27 spinocerebellar ataxia 2 33.3 VAPB UBQLN2 TARDBP SPG11 SOD1 SETX
28 inclusion body myopathy with paget disease of bone and frontotemporal dementia 33.0 VCP UBQLN2 TARDBP SOD1 HNRNPA1 FUS
29 amyotrophic lateral sclerosis 1 32.9 VCP VAPB UBQLN2 TARDBP SPG11 SOD1
30 perry syndrome 32.9 VCP TARDBP FUS DCTN1 C9orf72
31 frontotemporal dementia 32.8 VCP UBQLN2 TARDBP SOD1 NEFH LOC109504728
32 neuromuscular disease 32.7 SOD1 NEFH FIG4 DCTN1 C9orf72
33 progressive bulbar palsy 32.7 VAPB TARDBP SOD1 FUS C9orf72 ALS2
34 progressive muscular atrophy 32.6 VCP VAPB UBQLN2 TARDBP SOD1 FUS
35 motor neuron disease 32.3 VCP VAPB TARDBP SOD1 SIGMAR1 SETX
36 distal hereditary motor neuropathies 32.2 SETX DCTN1
37 muscular atrophy 31.2 VAPB TARDBP SIGMAR1 SETX HNRNPA1 FUS
38 pseudobulbar palsy 31.1 TARDBP C9orf72 ALS2
39 aphasia 31.1 VCP TARDBP LOC109504728 FUS C9orf72
40 supranuclear palsy, progressive, 1 31.0 VCP TARDBP SOD1 FUS DCTN1 C9orf72
41 semantic dementia 31.0 TARDBP C9orf72
42 progressive non-fluent aphasia 31.0 VCP C9orf72
43 movement disease 30.9 TARDBP FUS C9orf72
44 agraphia 30.9 TARDBP C9orf72
45 autosomal dominant cerebellar ataxia 30.9 VCP TARDBP SOD1 SETX FUS C9orf72
46 dysgraphia 30.9 TARDBP C9orf72
47 tooth disease 30.9 VCP SPG11 NEFH FIG4
48 pick disease of brain 30.8 VCP UBQLN2 TARDBP SOD1 NEFH FUS
49 spinal muscular atrophy 30.8 VAPB TARDBP SOD1 SIGMAR1 SETX HNRNPA1
50 nominal aphasia 30.8 VCP TARDBP FUS C9orf72

Graphical network of the top 20 diseases related to Lateral Sclerosis:



Diseases related to Lateral Sclerosis
Sources

Symptoms & Phenotypes for Lateral Sclerosis

About this section

UMLS symptoms related to Lateral Sclerosis:


ataxia, myoclonus, hemiplegia, muscular fasciculation

MGI Mouse Phenotypes related to Lateral Sclerosis:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.1 ALS2 C9orf72 CHCHD10 DCTN1 FIG4 NEFH
2 cellular MP:0005384 9.93 C9orf72 CHCHD10 DCTN1 NEFH RNF19A SETX
3 muscle MP:0005369 9.56 ALS2 CHCHD10 DCTN1 FIG4 SOD1 TARDBP
4 nervous system MP:0003631 9.47 ALS2 C9orf72 CHCHD10 DCTN1 FIG4 NEFH
Sources

Drugs & Therapeutics for Lateral Sclerosis

About this section

Drugs for Lateral Sclerosis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 372)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Mexiletine Approved, Investigational Phase 4 31828-71-4 4178
2
Minocycline Approved, Investigational Phase 4 10118-90-8 5281021
3 Anti-Inflammatory Agents Phase 4
4 Nootropic Agents Phase 4
5 Hormone Antagonists Phase 4
6 Hormones Phase 4
7 Thyrotropin-Releasing Hormone Phase 4
8 TA 0910 Phase 4
9
Olanzapine Approved, Investigational Phase 2, Phase 3 132539-06-1 4585
10
Sargramostim Approved, Investigational Phase 2, Phase 3 123774-72-1, 83869-56-1
11
Lenograstim Approved, Investigational Phase 2, Phase 3 135968-09-1
12
Guaifenesin Approved, Investigational, Vet_approved Phase 3 93-14-1 3516
13
Dextromethorphan Approved Phase 3 125-71-3 5360696 5362449
14
Quinidine Approved, Investigational Phase 3 56-54-2 441074
15
Ethanol Approved Phase 3 64-17-5 702
16
Citalopram Approved Phase 3 59729-33-8 2771
17
Zinc Approved, Investigational Phase 3 7440-66-6 32051
18
Mecasermin Approved, Investigational Phase 3 68562-41-4
19
Ceftriaxone Approved Phase 3 73384-59-5 5479530 5361919
20
Naltrexone Approved, Investigational, Vet_approved Phase 3 16590-41-3 5360515
21
Methylcobalamin Approved, Investigational Phase 3 13422-55-4
22
Edaravone Approved, Investigational Phase 3 89-25-8 70335
23
Hydroxocobalamin Approved Phase 3 13422-51-0 11953898 15589840
24
Sodium citrate Approved, Investigational Phase 3 68-04-2
25
Dopamine Approved Phase 3 51-61-6, 62-31-7 681
26
Riluzole Approved, Investigational Phase 3 1744-22-5 5070
27
Pramipexole Approved, Investigational Phase 3 104632-26-0 59868 119570
28
Lithium carbonate Approved Phase 2, Phase 3 554-13-2
29
Modafinil Approved, Investigational Phase 3 68693-11-8 4236
30
Tamsulosin Approved, Investigational Phase 3 106133-20-4 129211
31
Vitamin A Approved, Nutraceutical, Vet_approved Phase 2, Phase 3 68-26-8, 11103-57-4, 22737-96-8 445354 9904001
32
Coenzyme Q10 Approved, Investigational, Nutraceutical Phase 3 303-98-0 5281915
33
Folic acid Approved, Nutraceutical, Vet_approved Phase 3 59-30-3 6037
34
Cyanocobalamin Approved, Nutraceutical Phase 3 68-19-9 44176380
35
Citric acid Approved, Nutraceutical, Vet_approved Phase 3 77-92-9 311
36
Tyrosine Approved, Investigational, Nutraceutical Phase 3 60-18-4 6057
37 Nabiximols Investigational Phase 2, Phase 3 56575-23-6
38
Cobalamin Experimental Phase 3 13408-78-1 6857388
39
Simendan Investigational Phase 3 131741-08-7
40
Ibudilast Investigational Phase 2, Phase 3 50847-11-5 3671
41 retinol Phase 2, Phase 3
42 Retinol palmitate Phase 2, Phase 3
43 Adjuvants, Immunologic Phase 2, Phase 3
44 Anti-Arrhythmia Agents Phase 3
45 Cytochrome P-450 Enzyme Inhibitors Phase 3
46 Antiparasitic Agents Phase 3
47 Antitussive Agents Phase 3
48 Antimalarials Phase 3
49 Sodium Channel Blockers Phase 3
50 Chlorpheniramine, phenylpropanolamine drug combination Phase 3

Interventional clinical trials:

(show top 50) (show all 619)
# Name Status NCT ID Phase Drugs
1 Role of Non-invasive Ventilation in Amyotrophic Lateral Sclerosis: Volume Versus Pressure Mode Unknown status NCT00560287 Phase 4
2 Care (Canadian ALS Riluzole Evaluation) Multicentre Phase IV Comparative Study of the Effects of Riluzole 50mg Bid on the Survival of ALS Subjects Compared to Historical Controls Completed NCT00542412 Phase 4 Riluzole
3 Mexiletine for the Treatment of Muscle Cramps in ALS Completed NCT01811355 Phase 4 Mexiletine;Placebo
4 Feasibility of Telesurveillance and Home Cough Assistance for Amyotrophic Lateral Patients (ALS) Completed NCT00613899 Phase 4
5 Riluzole in Fragile X Syndrome: A Pilot Study Incorporating Biomarker Assay Completed NCT00895752 Phase 4 Riluzole
6 Modafinil for Treatment of Fatigue in ALS Patients: Pilot Study Completed NCT00614926 Phase 4 Modafinil;Placebo
7 Treatment of Childhood Regressive Autism With Minocycline: an Anti-Inflammatory Agent Active Within the CNS Completed NCT00409747 Phase 4 Minocycline
8 Multicenter, Randomized, Double-blind, Placebo-controlled, Phase IV Clinical Trial to Evaluate and Compare the Safety and Efficacy of C-Trelin OD Tab 5mg(Taltirelin Hydrate) in Patients With Ataxia Induced by Spinocerebellar Degeneration Recruiting NCT04107740 Phase 4 C-Trelin OD Tab(5mg Taltirelin Hydrate);Placebo
9 A Phase III, Multi-Center, Double-Blind, Placebo Controlled, Randomized Study of Creatine Monohydrate in Patients With Amyotrophic Lateral Sclerosis Unknown status NCT00069186 Phase 3 Creatine Monohydrate
10 Randomized, Placebo-controlled Parallel Group Study for the Evaluation of an Oral Dose of 10mg Olanzapine in Combination With Riluzole for the Treatment of Loss of Appetite in Patients With Amyotrophic Lateral Sclerosis (ALS) Unknown status NCT00876772 Phase 2, Phase 3 Olanzapine
11 Phase 2/3 Application of Botulinum Neurotoxin Type A in Salivary Glands as a Treatment of Chronic Drooling in Patients With Cerebral Palsy: A Controlled Clinical Trial. Unknown status NCT01489904 Phase 2, Phase 3
12 A Fase II, Randomized, Double-Blind, Placebo-Controlled, Multicentre Study for the Safety and Efficacy on Spasticity Symptoms of a Cannabis Sativa Extract in Motor Neuron Disease Patients Completed NCT01776970 Phase 2, Phase 3 Cannabis Sativa extract Oromucosal spray
13 A Long-Term Study in Patients With Amyotrophic Lateral Sclerosis (ALS) Completed NCT00445172 Phase 2, Phase 3 E0302 (mecobalamin)
14 The Effect of Granulocyte Colony Stimulating Factor (GCSF) in the Treatment of Amyotrophic Lateral Sclerosis (ALS) Patients Referred to Tehran Imam Khomeini and Shariati Hospital Centers in 2013 Completed NCT01825551 Phase 2, Phase 3 Granulocyte Colony Stimulating Factor;Placebo
15 Effect of Intrathecal Administration of Hematopoietic Stem Cells in Patients With Amyotrophic Lateral Sclerosis (ALS) Completed NCT01933321 Phase 2, Phase 3
16 A Double-Blind Controlled, Multicenter Phase II/III Study to Assess the Safety and Efficacy of AVP-923 (Dextromethorphan/Quinidine) in the Treatment of Pseudobulbar Affect in Patients With Amyotrophic Lateral Sclerosis Completed NCT00021697 Phase 3 AVP-923
17 A Phase II/III Study in Patients With Amyotrophic Lateral Sclerosis (ALS) Completed NCT00444613 Phase 2, Phase 3 E0302 (mecobalamin);E0302 (mecobalamin);Placebo
18 A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study of the Safety and Efficacy of Dexpramipexole in Subjects With Amyotrophic Lateral Sclerosis Completed NCT01281189 Phase 3 Dexpramipexole;Placebo
19 Phase 2-3 - Memantine for Disability in Amyotrophic Lateral Sclerosis Completed NCT00353665 Phase 2, Phase 3 Memantine (Ebixa);riluzole;Placebo
20 A Randomized, Double-Blind, Placebo-Controlled Study of Safety and Efficacy of Botulinum Toxin Type B (Myobloc) in Sialorrhea in Amyotrophic Lateral Sclerosis Completed NCT00125203 Phase 2, Phase 3 Botulinum toxin type B (Myobloc)
21 A Phase 3, Open-Label Extension Study of Tirasemtiv for Patients With Amyotrophic Lateral Sclerosis (ALS) Who Completed VITALITY-ALS (CY 4031) Completed NCT02936635 Phase 3 tirasemtiv
22 An Expanded Controlled Study of MCI-186 for Treatment of Amyotrophic Lateral Sclerosis in Double-Blind, Parallel-Group, Placebo-Controlled Manner (Phase 3) Completed NCT00424463 Phase 3 MCI-186;Placebo of MCI-186
23 Efficacy and Safety Study of MCI-186 for Treatment of the Patients With Amyotrophic Lateral Sclerosis (ALS) 2 Completed NCT01492686 Phase 3 MCI-186;Placebo;MCI-186 in open label phase
24 Multicenter, Randomised, Double-blind, Placebo-controlled, Parallel Group, Phase 2/3 Study to Compare the Efficacy and Safety of Masitinib Completed NCT02588677 Phase 2, Phase 3 Masitinib (4.5);Riluzole;Placebo;Masitinib (3.0)
25 An Open-label Safety Extension Study of TRO19622 in Amyotrophic Lateral Sclerosis (ALS) Patients Treated With Riluzole Completed NCT01285583 Phase 2, Phase 3 TRO19622
26 An Exploratory Study of MCI-186 for Treatment of Amyotrophic Lateral Sclerosis (Severity Classification III) in Double-Blind, Parallel-Group, Placebo-Controlled Manner Completed NCT00415519 Phase 3 MCI-186;Placebo of MCI-186
27 A Confirmatory Study of MCI-186 for Treatment of Amyotrophic Lateral Sclerosis in Double-blind, Parallel-group, Placebo-controlled Manner. Completed NCT00330681 Phase 3 MCI-186;Placebo of MCI-186
28 An Open-label, 8- Week, Flexible Dose Trial of Escitalopram (Lexapro®) in Comorbid Major Depression With Amyotrophic Lateral Sclerosis and Multiple Sclerosis Completed NCT00965497 Phase 3 escitalopram
29 Insulin-like Growth Factor-1 in Amyotrophic Lateral Sclerosis (ALS) Completed NCT00035815 Phase 3 Insulin like growth factor, type 1;Placebo
30 Noninvasive Ventilation in ALS Patients With Mild Respiratory Involvement Completed NCT00386464 Phase 2, Phase 3
31 A Randomized, Double-Blind, Placebo-Controlled Sequential Clinical Trial of Sodium Valproate in ALS Completed NCT00136110 Phase 3 Sodium Valproate
32 Randomized Crossover Design Trial of Vitamin E vs Placebo for Treatment of Cramps in Amyotrophic Lateral Sclerosis. Completed NCT00372879 Phase 3
33 A Phase 3, Multi-National, Double-Blind, Randomized, Placebo-Controlled, Stratified, Parallel Group, Study to Evaluate the Safety, Tolerability and Efficacy of Tirasemtiv in Patients With Amyotrophic Lateral Sclerosis (ALS) Completed NCT02496767 Phase 3 tirasemtiv;Placebo tablets;Riluzole 50 MG
34 Phase II/III, Multicenter, Randomized, Parallel Group, Double-blind, Placebo Controlled Study to Assess Safety and Efficacy of TRO19622 in Amyotrophic Lateral Sclerosis (ALS) Patients Treated With Riluzole Completed NCT00868166 Phase 3 Olesoxime;Placebo Comparator;Riluzole
35 Study of Dopamine and Serotonin Transporters in Patients With Amyotrophic Lateral Sclerosis and Controls. Analysis With 123I-FP-CIT (Datscan) and 123I-ADAM Brain SPECT Completed NCT01160263 Phase 3 SPECT : 123 I-FP-CIT (DATSCAN) and 123I-ADAM
36 A European, Randomised, Double-blind, Active Comparator Controlled, Cross-over, Efficacy and Safety Study of a New 10% Ready To-use Liquid Human Intravenous Immunoglobulin (I10E) Versus Kiovig® in Patients With Multifocal Motor Neuropathy Completed NCT01951924 Phase 3 Biological : I10E (Human normal Immunoglobulin for intravenous administration 100mg/mL);Biological: Kiovig® (Human normal Immunoglobulin for intravenous administration 100mg/mL)
37 Minocycline to Treat Amyotrophic Lateral Sclerosis Completed NCT00047723 Phase 3 minocycline
38 Phase II/III Randomized, Placebo-Controlled Trial of Arimoclomol in SOD1 Positive Familial Amyotrophic Lateral Sclerosis (ALS) Completed NCT00706147 Phase 2, Phase 3 Arimoclomol;Placebo
39 Clinical Trial Ceftriaxone in Subjects With Amyotrophic Lateral Sclerosis (ALS) Completed NCT00349622 Phase 3 ceftriaxone
40 Repetitive Transcranial Magnetic Stimulation in Amyotrophic Lateral Sclerosis Completed NCT00833820 Phase 2, Phase 3
41 A Phase 3, Multicenter, Double-Blind, Placebo-Controlled, Single-Treatment Efficacy and Safety Study of MYOBLOC® (Part A) Followed by Open-Label, Multiple-Treatment With MYOBLOC® (Part B) in the Treatment of Troublesome Sialorrhea in Adult Subjects Completed NCT01994109 Phase 3 MYOBLOC
42 A Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Assess the Safety and Efficacy and to Determine the Pharmacokinetics of Two Doses of AVP-923 (Dextromethorphan/Quinidine) in the Treatment of Pseudobulbar Affect (PBA) in Patients With Amyotrophic Lateral Sclerosis (ALS) and Multiple Sclerosis (MS) Completed NCT00573443 Phase 3 dextromethorphan hydrobromide 20 mg and quinidine sulfate 10 mg;dextromethorphan hydrobromide 30 mg and quinidine sulfate 10 mg;Placebo
43 Efficacy of Riluzole in Patients With Cervical Spondylotic Myelopathy Undergoing Surgical Treatment. A Randomized, Double-Blind, Placebo-controlled Multi-Center Study Completed NCT01257828 Phase 3 riluzole;Placebo medication
44 Double-Blind, Randomised, Two-Armed Study for the Evaluation of Efficacy and Safety of Minocycline for Treatment Completed NCT00146809 Phase 3 Minocyline
45 A Randomized Placebo-Controlled, Crossover-Design Study of the Effects of Low Dose Naltrexone on Quality of Life as Measured by the Multiple Sclerosis Quality of Life Inventory (MSQLI54) Completed NCT00501696 Phase 3 4.5 mg Naltrexone;Naltrexone
46 Preventing Loss of Independence Through Exercise (PLIE) in Persons With Dementia Completed NCT02350127 Phase 2, Phase 3
47 A Double Blind Randomized Study of Minocycline for the Treatment of Negative and Cognitive Symptoms in Early-Phase Schizophrenia Completed NCT00733057 Phase 3 Minocycline;Placebo (200 mg/day)
48 Japanese Early-stage Clinical Trial of Ultra-high Dose Methylcobalamin for Amyotrophic Lateral Sclerosis: a Pivotal Phase 3 Randomized Controlled Study Recruiting NCT03548311 Phase 3 methylcobalamin;saline solution
49 A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Cu(II)ATSM in Patients With Amyotrophic Lateral Sclerosis/Motor Neuron Disease Recruiting NCT04082832 Phase 2, Phase 3 Cu(II)ATSM;Placebos
50 A Randomised, Double-blind, Single-centre Study on the Safety, Tolerability and Efficacy of Cannabis Based Medicine Extract (CannTrust CBD Oil) in Slowing the Disease Progression in Amyotrophic Lateral Sclerosis or Motor Neurone Disease Patients Recruiting NCT03690791 Phase 3 CannTrust CBD Oil (capsule);Placebo (capsule)

Search NIH Clinical Center for Lateral Sclerosis

Cochrane evidence based reviews: motor neuron disease

Sources

Genetic Tests for Lateral Sclerosis

About this section
Sources

Anatomical Context for Lateral Sclerosis

About this section

MalaCards organs/tissues related to Lateral Sclerosis:

40
Brain, Spinal Cord, Bone, Testes, Cortex, Skeletal Muscle, Skin
Sources

Publications for Lateral Sclerosis

About this section

Articles related to Lateral Sclerosis:

(show top 50) (show all 22396)
# Title Authors PMID Year
1
Comparative proteomes change and possible role in different pathways of microRNA-21a-5p in a mouse model of spinal cord injury. 61
31823891 2020
2
Intralingual and Intrapleural AAV Gene Therapy Prolongs Survival in a SOD1 ALS Mouse Model. 61
31970202 2020
3
Novel small molecule TRVA242 targets neuromuscular junction in amyotrophic lateral sclerosis. 61
31823882 2020
4
Type XIX collagen: a promising biomarker from the basement membranes. 61
31823868 2020
5
Using induced pluripotent stem cell neuronal models to study neurodegenerative diseases. 61
30898538 2020
6
Longitudinal transcriptomic analysis of altered pathways in a CHMP2Bintron5-based model of ALS-FTD. 61
31837425 2020
7
Production of the neurotoxin beta-N-methylamino-l-alanine may be triggered by agricultural nutrients: An emerging public health issue. 61
31812811 2020
8
Unveiling the structural features of nonnative trimers of human superoxide dismutase 1. 61
31734464 2020
9
Re: "Facial nerve atrophy in patients with amyotrophic lateral sclerosis: Evaluation with fast imaging employing steady-state acquisition (FIESTA)". 61
31397967 2020
10
Facial nerve atrophy in patients with amyotrophic lateral sclerosis: Evaluation with fast imaging employing steady-state acquisition (FIESTA). 61
31400058 2020
11
Causal effects of serum metabolites on amyotrophic lateral sclerosis: A Mendelian randomization study. 61
31669200 2020
12
Dysregulation of Rac or Rho elicits death of motor neurons and activation of these GTPases is altered in the G93A mutant hSOD1 mouse model of amyotrophic lateral sclerosis. 61
31931138 2020
13
Primary lateral sclerosis (PLS) functional rating scale: PLS-specific clinimetric scale. 61
31758557 2020
14
The clinical and radiological profile of primary lateral sclerosis: an annotation on its pathological and clinical background. 61
31807916 2020
15
Leucine-rich repeat kinase 2 and lysosomal dyshomeostasis in Parkinson disease. 61
31693760 2020
16
Workshop summary: Potential usefulness and feasibility of a US National Mesothelioma Registry. 61
31743489 2020
17
Oxidative misfolding of Cu/Zn-superoxide dismutase triggered by non-canonical intramolecular disulfide formation. 61
31863908 2020
18
A synthetic Pur-based peptide binds and alters G-quadruplex secondary structure present in the expanded RNA repeat of C9orf72 ALS/FTD. 61
32035967 2020
19
Combined intramuscular and intraspinal transplant of bone marrow cells improves neuromuscular function in the SOD1G93A mice. 61
32033585 2020
20
Structural basis of the zinc-induced cytoplasmic aggregation of the RNA-binding protein SFPQ. 61
32034402 2020
21
Gene therapy for overexpressing Neuregulin 1 type I in skeletal muscles promotes functional improvement in the SOD1G93A ALS mice. 61
32032731 2020
22
New phenotype of DCTN1-related spectrum: early-onset dHMN plus congenital foot deformity. 61
32023010 2020
23
Changes in hydrophobicity mainly promotes the aggregation tendency of ALS associated SOD1 mutants. 61
31669277 2020
24
Misconnecting the dots: altered mitochondrial protein-protein interactions and their role in neurodegenerative disorders. 61
31986926 2020
25
The upper cervical spinal cord in ALS assessed by cross-sectional and longitudinal 3T MRI. 61
32020025 2020
26
Recommendations for measuring whisker movements and locomotion in mice with sensory, motor and cognitive deficits. 61
31785300 2020
27
Modulating ALS-Related Amyloidogenic TDP-43307-319 Oligomeric Aggregates with Computationally Derived Therapeutic Molecules. 61
31846303 2020
28
On-chip 3D neuromuscular model for drug screening and precision medicine in neuromuscular disease. 61
31932771 2020
29
Optimizing intracellular antibodies (intrabodies/nanobodies) to treat neurodegenerative disorders. 61
31669671 2020
30
Executive, language and fluency dysfunction are markers of localised TDP-43 cerebral pathology in non-demented ALS. 61
31515300 2020
31
DNL104, a Centrally Penetrant RIPK1 Inhibitor, Inhibits RIP1 Kinase Phosphorylation in a Randomized Phase I Ascending Dose Study in Healthy Volunteers. 61
31437302 2020
32
Posteroanterior cervical transcutaneous spinal stimulation targets ventral and dorsal nerve roots. 61
31887616 2020
33
Modeling cell-autonomous motor neuron phenotypes in ALS using iPSCs. 61
31759135 2020
34
Frontotemporal dementia-associated protein "phosphorylated TDP-43" localizes to atherosclerotic lesions of human carotid and main cerebral arteries. 61
31259382 2020
35
Sorting Rare ALS Genetic Variants by Targeted Re-Sequencing Panel in Italian Patients: OPTN, VCP, and SQSTM1 Variants Account for 3% of Rare Genetic Forms. 61
32028661 2020
36
TNF receptor associated factor 6 interacts with ALS-linked misfolded superoxide dismutase 1 and promotes aggregation. 61
32029478 2020
37
IGF1R regulates retrograde axonal transport of signalling endosomes in motor neurons. 61
32030864 2020
38
Reactive oxygen species (ROS) and their impact in neurodegenerative diseases: literature landscape analysis. 61
32030995 2020
39
Active poly-GA vaccination prevents microglia activation and motor deficits in a C9orf72 mouse model. 61
31858749 2020
40
Genetic analyses uncover pleiotropic compensatory roles for Drosophila Nucleobindin-1 in inositol trisphosphate-mediated intracellular calcium homeostasis. 61
31557446 2020
41
Association Between Neurological Disorders and Death by Suicide in Denmark. 61
32016308 2020
42
Protective effect of hydrogen sulfide on oxidative stress-induced neurodegenerative diseases. 61
31552888 2020
43
A mutation in p62 protein (p. R321C), associated to Paget's disease of bone, causes a blockade of autophagy and an activation of NF-kB pathway. 61
32036052 2020
44
Expanding therapeutic opportunities for neurodegenerative diseases: A perspective on the important role of phenotypic screening. 61
31889605 2020
45
Gene therapy for neurological disorders: challenges and recent advancements. 61
31195838 2020
46
Primary lateral sclerosis: consensus diagnostic criteria. 61
32029539 2020
47
New Roles for Canonical Transcription Factors in Repeat Expansion Diseases. 61
31837826 2020
48
Neuronal autophagy declines substantially with age and is rescued by overexpression of WIPI2. 61
31794336 2020
49
Development of novel small molecules for the treatment of ALS. 61
31928838 2020
50
Genome-wide synthetic lethal CRISPR screen identifies FIS1 as a genetic interactor of ALS-linked C9ORF72. 61
31843624 2020
Sources

Variations for Lateral Sclerosis

About this section
Sources

Expression for Lateral Sclerosis

About this section
Search GEO for disease gene expression data for Lateral Sclerosis.
Sources

Pathways for Lateral Sclerosis

About this section

Pathways related to Lateral Sclerosis according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Neuroscience 4
11.89 TARDBP SOD1 SIGMAR1 NEFH DCTN1
2
Cytoskeleton remodeling Neurofilaments 22
Show member pathways
 11.37 PRPH NEFH DCTN1
3
Amyotrophic lateral sclerosis (ALS) 1 36
Show member pathways
 10.98 SOD1 PRPH NEFH ALS2
Sources

GO Terms for Lateral Sclerosis

About this section

Cellular components related to Lateral Sclerosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytoplasm GO:0005737 10.17 VCP VAPB UBQLN2 TARDBP SPG11 SOD1
2 lipid droplet GO:0005811 9.43 VCP SIGMAR1 FIG4
3 cytoplasmic stress granule GO:0010494 9.33 VCP TARDBP C9orf72
4 growth cone GO:0030426 9.26 SIGMAR1 SETX C9orf72 ALS2
5 axon GO:0030424 9.1 SPG11 SETX NEFH DCTN1 C9orf72 ALS2

Biological processes related to Lateral Sclerosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 locomotory behavior GO:0007626 9.43 SOD1 FIG4 ALS2
2 gene expression GO:0010467 9.32 TARDBP FUS
3 regulation of autophagosome assembly GO:2000785 9.16 UBQLN2 C9orf72
4 neurofilament cytoskeleton organization GO:0060052 8.96 SOD1 NEFH
5 maintenance of synapse structure GO:0099558 8.62 DCTN1 CHCHD10

Molecular functions related to Lateral Sclerosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 dynein complex binding GO:0070840 8.62 NEFH DCTN1
Sources

Sources for Lateral Sclerosis

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....